Positioning Natrecor in CHF

Although Scios Inc. plans to proceed to the FDA with the positive Phase III results of its Natrecor b-type natriuretic peptide (BNP) in acute congestive heart failure, the company still must address key issues to position the drug in a market with a number of existing products. The products used to treat CHF are almost entirely generic drugs, making them cheap, and although each has shortcomings, SCIO will need to convince a market that Natrecor is safer, better and easier to

Read the full 814 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE